These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 10659047)

  • 21. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.
    Someya K; Cecilia D; Ami Y; Nakasone T; Matsuo K; Burda S; Yamamoto H; Yoshino N; Kaizu M; Ando S; Okuda K; Zolla-Pazner S; Yamazaki S; Yamamoto N; Honda M
    J Virol; 2005 Feb; 79(3):1452-62. PubMed ID: 15650171
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prime-boost vaccination using recombinant Mycobacterium bovis BCG and recombinant vaccinia virus DIs harboring HIV-1 CRF01_AE gag in mice: influence of immunization routes.
    Promkhatkaew D; Matsuo K; Pinyosukhee N; Thongdeejaroen W; Leang-Aramgul P; Sawanpanyalert P; Warachit P
    Southeast Asian J Trop Med Public Health; 2009 Mar; 40(2):273-81. PubMed ID: 19323012
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Progress toward an HIV vaccine.
    Letvin NL
    Annu Rev Med; 2005; 56():213-23. PubMed ID: 15660510
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guérin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity.
    Ami Y; Izumi Y; Matsuo K; Someya K; Kanekiyo M; Horibata S; Yoshino N; Sakai K; Shinohara K; Matsumoto S; Yamada T; Yamazaki S; Yamamoto N; Honda M
    J Virol; 2005 Oct; 79(20):12871-9. PubMed ID: 16188989
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review.
    Girard MP; Osmanov S; Assossou OM; Kieny MP
    Vaccine; 2011 Aug; 29(37):6191-218. PubMed ID: 21718747
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Executive summary and recommendations from WHO/UNAIDS and AAVP consultation on: 'The inclusion of adolescents in HIV vaccine trials', 16-18 March 2006 in Gaborone, Botswana.
    ; Osmanov S
    AIDS; 2007 Sep; 21(14):W1-10. PubMed ID: 17721089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials.
    Gilbert PB; Chiu YL; Allen M; Lawrence DN; Chapdu C; Israel H; Holman D; Keefer MC; Wolff M; Frey SE;
    Vaccine; 2003 Jun; 21(21-22):2933-47. PubMed ID: 12798637
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV vaccine efficacy trials: towards the future of HIV prevention.
    Kim D; Elizaga M; Duerr A
    Infect Dis Clin North Am; 2007 Mar; 21(1):201-17, x. PubMed ID: 17502236
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression and immunogenicity of recombinant Mycobacterium bovis Bacillus Calmette-Guérin strains secreting the antigen ESAT-6 from Mycobacterium tuberculosis in mice.
    Wang LM; Shi CH; Fan XL; Xue Y; Bai YL; Xu ZK
    Chin Med J (Engl); 2007 Jul; 120(14):1220-5. PubMed ID: 17697571
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A prime-boost immunisation regimen using recombinant BCG and Pr55(gag) virus-like particle vaccines based on HIV type 1 subtype C successfully elicits Gag-specific responses in baboons.
    Chege GK; Thomas R; Shephard EG; Meyers A; Bourn W; Williamson C; Maclean J; Gray CM; Rybicki EP; Williamson AL
    Vaccine; 2009 Jul; 27(35):4857-66. PubMed ID: 19520196
    [TBL] [Abstract][Full Text] [Related]  

  • 31. What hope is there for an HIV vaccine?
    Witten G
    S Afr Med J; 2004 Oct; 94(10):831. PubMed ID: 15532757
    [No Abstract]   [Full Text] [Related]  

  • 32. Manipulation of BCG vaccine: a double-edged sword.
    Singh VK; Srivastava R; Srivastava BS
    Eur J Clin Microbiol Infect Dis; 2016 Apr; 35(4):535-43. PubMed ID: 26810060
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines.
    Aldovini A; Young RA
    Nature; 1991 Jun; 351(6326):479-82. PubMed ID: 2046750
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MUC1-based recombinant Bacillus Calmette-Guerin vaccines as candidates for breast cancer immunotherapy.
    Yuan S; Shi C; Liu L; Han W
    Expert Opin Biol Ther; 2010 Jul; 10(7):1037-48. PubMed ID: 20420512
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase 1 clinical trials of the National Institutes of Health Vaccine Research Center HIV/AIDS candidate vaccines.
    Robinson HL; Weinhold KJ
    J Infect Dis; 2006 Dec; 194(12):1625-7. PubMed ID: 17109331
    [No Abstract]   [Full Text] [Related]  

  • 36. Immunogenicity and protective efficacy of heterologous prime-boost regimens with mycobacterial vaccines and recombinant adenovirus- and poxvirus-vectored vaccines against murine tuberculosis.
    You Q; Wu Y; Wu Y; Wei W; Wang C; Jiang D; Yu X; Zhang X; Wang Y; Tang Z; Jiang C; Kong W
    Int J Infect Dis; 2012 Nov; 16(11):e816-25. PubMed ID: 22921259
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Public health. A sound rationale needed for phase III HIV-1 vaccine trials.
    Burton DR; Desrosiers RC; Doms RW; Feinberg MB; Gallo RC; Hahn B; Hoxie JA; Hunter E; Korber B; Landay A; Lederman MM; Lieberman J; McCune JM; Moore JP; Nathanson N; Picker L; Richman D; Rinaldo C; Stevenson M; Watkins DI; Wolinsky SM; Zack JA
    Science; 2004 Jan; 303(5656):316. PubMed ID: 14726576
    [No Abstract]   [Full Text] [Related]  

  • 38. Immunogenicity and safety of the vaccinia virus LC16m8Δ vector expressing SIV Gag under a strong or moderate promoter in a recombinant BCG prime-recombinant vaccinia virus boost protocol.
    Sato H; Jing C; Isshiki M; Matsuo K; Kidokoro M; Takamura S; Zhang X; Ohashi T; Shida H
    Vaccine; 2013 Aug; 31(35):3549-57. PubMed ID: 23731631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The challenges of HIV vaccine development and testing.
    Burgers WA; Williamson C
    Best Pract Res Clin Obstet Gynaecol; 2005 Apr; 19(2):277-91. PubMed ID: 15778116
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mycobacterial codon optimization enhances antigen expression and virus-specific immune responses in recombinant Mycobacterium bovis bacille Calmette-Guérin expressing human immunodeficiency virus type 1 Gag.
    Kanekiyo M; Matsuo K; Hamatake M; Hamano T; Ohsu T; Matsumoto S; Yamada T; Yamazaki S; Hasegawa A; Yamamoto N; Honda M
    J Virol; 2005 Jul; 79(14):8716-23. PubMed ID: 15994765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.